with suspected pulmonary embolism. J Thromb Haemost. 2004 Aug;2(8):1247-55. \[[PubMed: 15304025](https://pubmed.ncbi.nlm.nih.gov/15304025)\] 63. Coutance G, Cauderlier E, Ehtisham J, Hamon M, Hamon M. The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a meta-analysis. Crit Care. 2011;15(2):R103. \[[PMC free article: PMC3219376](/pmc/articles/PMC3219376/)\] \[[PubMed: 21443777](https://pubmed.ncbi.nlm.nih.gov/21443777)\] 64. Hugli O, Righini M, Le Gal G, Roy PM, Sanchez O, Verschuren F, Meyer G, Bounameaux H, Aujesky D. The pulmonary embolism rule-out criteria (PERC) rule does not safely exclude pulmonary embolism. J Thromb Haemost. 2011 Feb;9(2):300-4. \[[PubMed: 21091866](https://pubmed.ncbi.nlm.nih.gov/21091866)\] 65. Stein PD, Hull RD, Matta F, Yaekoub AY, Liang J. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med. 2009 Oct;122(10):919-30. \[[PubMed: 19682670](https://pubmed.ncbi.nlm.nih.gov/19682670)\] 66. Cossette B, Pelletier ME, Carrier N, Turgeon M, Leclair C, Charron P, Echenberg D, Fayad T, Farand P. Evaluation of bleeding risk in patients exposed to therapeutic unfractionated or low-molecular-weight heparin: a cohort study in the context of a quality improvement initiative. Ann Pharmacother. 2010 Jun;44(6):994-1002. \[[PubMed: 20442353](https://pubmed.ncbi.nlm.nih.gov/20442353)\] 67. Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva AM, Come PC, Lee RT, Parker JA. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993 Feb 27;341(8844):507-11. \[[PubMed: 8094768](https://pubmed.ncbi.nlm.nih.gov/8094768)\] 68. Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, Zonzin P, Zanuttini D, Barbaresi F, Agnelli G. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol. 1992 Sep;20(3):520-6. \[[PubMed: 1512328](https://pubmed.ncbi.nlm.nih.gov/1512328)\] 69. Daniels LB, Parker JA, Patel SR, Grodstein F, Goldhaber SZ. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol. 1997 Jul 15;80(2):184-8. \[[PubMed: 9230156](https://pubmed.ncbi.nlm.nih.gov/9230156)\] 70. Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, Meyer G, Perrier A. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015 Mar 07;36(10):605-14. \[[PMC free article: PMC4352209](/pmc/articles/PMC4352209/)\] \[[PubMed: 24917641](https://pubmed.ncbi.nlm.nih.gov/24917641)\] 71. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Gali√® N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren